[go: up one dir, main page]

MX2016010899A - A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22. - Google Patents

A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22.

Info

Publication number
MX2016010899A
MX2016010899A MX2016010899A MX2016010899A MX2016010899A MX 2016010899 A MX2016010899 A MX 2016010899A MX 2016010899 A MX2016010899 A MX 2016010899A MX 2016010899 A MX2016010899 A MX 2016010899A MX 2016010899 A MX2016010899 A MX 2016010899A
Authority
MX
Mexico
Prior art keywords
human insulin
desb27
lysine
des
insulin analogue
Prior art date
Application number
MX2016010899A
Other languages
English (en)
Other versions
MX368387B (es
Inventor
Madsen Peter
Børglum Kjeldsen Thomas
HOSTRUP Susanne
Münzel Martin
Ulrich Hjørringgaard Claudia
Fledelius Christian
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2016010899A publication Critical patent/MX2016010899A/es
Publication of MX368387B publication Critical patent/MX368387B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)

Abstract

La presente invención se relaciona con los campos terapéuticos de fármacos para afecciones médicas que se relacionan con la diabetes. Más específicamente, la invención se relaciona con nuevos derivados acilados de los análogos de insulina humana. La invención también proporciona composiciones farmacéuticas que comprenden tales derivados de insulina, y se relaciona con el uso de tales derivados para el tratamiento o prevención de afecciones médicas que se relacionan con la diabetes.
MX2016010899A 2014-02-28 2015-02-26 A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22. MX368387B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14157215 2014-02-28
PCT/EP2015/053989 WO2015128403A2 (en) 2014-02-28 2015-02-26 Novel insulin derivatives and the medical uses hereof

Publications (2)

Publication Number Publication Date
MX2016010899A true MX2016010899A (es) 2016-11-18
MX368387B MX368387B (es) 2019-10-01

Family

ID=50184804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010899A MX368387B (es) 2014-02-28 2015-02-26 A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22.

Country Status (23)

Country Link
US (1) US10040839B2 (es)
EP (1) EP3110840B1 (es)
JP (1) JP6580583B2 (es)
KR (1) KR20160125988A (es)
CN (1) CN106459171B (es)
AR (1) AR099569A1 (es)
AU (1) AU2015222135B2 (es)
BR (1) BR112016017193A2 (es)
CA (1) CA2941103A1 (es)
DK (1) DK3110840T3 (es)
ES (1) ES2831848T3 (es)
HR (1) HRP20201732T1 (es)
HU (1) HUE051355T2 (es)
IL (1) IL246757B (es)
MX (1) MX368387B (es)
PL (1) PL3110840T3 (es)
PT (1) PT3110840T (es)
RS (1) RS61137B1 (es)
RU (1) RU2684456C2 (es)
SA (1) SA516371705B1 (es)
SI (1) SI3110840T1 (es)
TW (1) TWI686403B (es)
WO (1) WO2015128403A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015131902A1 (en) * 2014-03-07 2015-09-11 Jørgensen Klavs Holger Novel fast acting insulin preparations
BR112018002416A2 (pt) 2015-08-25 2018-09-18 Novo Nordisk As derivados de insulina e seus usos médicos
JP7286160B2 (ja) * 2016-11-21 2023-06-05 ケース ウェスタン リザーブ ユニバーシティ 安定性が増強された速効性インスリン類似体
KR101909052B1 (ko) * 2017-02-09 2018-10-17 강원대학교산학협력단 인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물
US11471537B2 (en) * 2017-04-05 2022-10-18 Novo Nordisk A/S Oligomer extended insulin-Fc conjugates
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
JP2020531451A (ja) * 2017-08-17 2020-11-05 ノヴォ ノルディスク アー／エス 新規のアシル化インスリン類似体およびそれらの使用
MX2020004251A (es) 2017-10-19 2021-05-27 Mona E Buice Composición tópica para cicatrización mejorada de heridas abiertas.
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2020120479A1 (en) 2018-12-11 2020-06-18 Sanofi Peptide binder
US12312419B2 (en) 2019-02-13 2025-05-27 Sumitomo Pharma Co., Ltd. Hemiasterlin derivative having cysteine residue
WO2020166592A1 (ja) * 2019-02-13 2020-08-20 大日本住友製薬株式会社 ヘミアスタリン誘導体とその抗体薬物複合体
US20220306695A1 (en) * 2019-08-27 2022-09-29 Zp Spv 3 K/S Compstatin analogues and their medical uses
FI4073097T3 (fi) 2019-12-11 2024-08-13 Novo Nordisk As Uusia insuliinianalogeja ja niiden käyttötapoja
CA3166494A1 (en) * 2019-12-30 2021-07-08 Gan & Lee Pharmaceuticals Co., Ltd. Insulin derivative
US20240374692A1 (en) * 2021-05-24 2024-11-14 Sunshine Lake Pharma Co., Ltd. A novel acylated insulin analog

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381274A (en) 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3864325A (en) 1971-11-18 1975-02-04 Nat Res Dev (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
JPH04502465A (ja) * 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
EP0506792B1 (en) * 1989-12-21 1995-05-17 Novo Nordisk A/S Insulin preparations containing nicotinic acid or nicotinamide
KR100310122B1 (ko) 1993-09-17 2002-04-24 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 아실화된인슐린
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
KR19980703039A (ko) 1995-03-17 1998-09-05 켈스버그 라아스 인슐린 유도체
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
BR9808285A (pt) 1997-03-20 2000-05-16 Novo Nordisk As Cristais de insulina isentos de zinco, formulação terapêutica em pó, processo para a preparação de cristais de insulina isentos de zinco, uso de cristais isentos de zinco, e, processo para o tratamento de diabetes mellitus
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
PE123799A1 (es) 1997-10-24 1999-12-13 Lilly Co Eli Composiciones insolubles de insulina
ES2202899T3 (es) 1997-10-24 2004-04-01 Novo Nordisk A/S Agregados de derivados de la insulina humana.
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
EP1044016B1 (en) 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
CA2334859A1 (en) 1998-06-12 1999-12-23 Kings College London Insulin analogue
AU5454200A (en) 1999-06-29 2001-01-31 Eli Lilly And Company Protamine-free insoluble acylated insulin compositions
WO2001093837A2 (en) 2000-06-08 2001-12-13 Eli Lilly And Company Protein powder for pulmonary delivery
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
EP1453860A2 (en) 2001-12-02 2004-09-08 Novo Nordisk A/S Novel glucose-dependant insulins
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
WO2003075950A1 (en) 2002-03-13 2003-09-18 Novo Nordisk A/S Minimising body weight gain in insulin treatment
US20040138099A1 (en) 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
WO2004096854A2 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
US20060183667A1 (en) 2003-07-11 2006-08-17 Novo Nordisk A/S Stabilised insulin compositions
EP1644411A2 (en) 2003-07-11 2006-04-12 Novo Nordisk A/S Stabilised insulin compositions
EP2264065B1 (en) 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
DK1660047T3 (en) 2003-08-13 2014-03-10 Biocon Ltd MICROPARTICALLY FATIC ACID SALT SOLID DOSAGE FORMS FOR THERAPEUTIC AGENTS
JP2007532096A (ja) 2003-11-14 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ アシル化されたインスリンの製造方法
CN1902226A (zh) 2003-12-03 2007-01-24 诺和诺德公司 单链胰岛素
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
WO2006082205A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP1846446B1 (en) 2005-02-02 2013-06-26 Novo Nordisk A/S Insulin derivatives
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
US8722620B2 (en) 2006-02-27 2014-05-13 Novo Nordisk A/S Insulin derivatives
EP2024390B1 (en) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
ES2548393T3 (es) 2006-05-09 2015-10-16 Novo Nordisk A/S Derivado de insulina
EP2076242B8 (en) 2006-07-27 2013-02-20 Nektar Therapeutics Aerosolizable formulation comprising insulin for pulmonary delivery
WO2008015099A2 (en) 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
BRPI0717098B8 (pt) * 2006-09-22 2021-05-25 Novo Nordisk As análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação
WO2008145721A2 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
WO2009015456A1 (en) 2007-07-30 2009-02-05 Generex Pharmaceuticals Inc. Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
CN101784562B (zh) * 2007-08-15 2016-07-13 诺沃-诺迪斯克有限公司 具有酰基和亚烷基二醇部分的胰岛素类似物
WO2009060071A1 (en) 2007-11-08 2009-05-14 Novo Nordisk A/S Insulin derivative
DK2597103T3 (en) 2007-11-16 2017-02-13 Novo Nordisk As Stable pharmaceutical compositions comprising liraglutide and degludec
EP2217265B1 (en) 2007-11-20 2017-05-10 Ambrx, Inc. Modified insulin polypeptides and their uses
EP2254905B1 (en) * 2008-03-14 2016-12-14 Novo Nordisk A/S Protease-stabilized insulin analogues
PT2254906T (pt) 2008-03-18 2017-01-03 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
CN106317164A (zh) 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
MX2011004357A (es) 2008-10-30 2011-05-23 Novo Nordisk As Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyeccion menor que a diario.
CA2744558A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2011000823A1 (en) 2009-06-30 2011-01-06 Novo Nordisk A/S Insulin derivatives
MA33466B1 (fr) * 2009-07-31 2012-07-03 Sanofi Aventis Deutschland Composition d'insuline à longue duree d'action
CN107029212A (zh) 2010-05-10 2017-08-11 诺沃—诺迪斯克有限公司 用于制备胰岛素‑锌复合物的方法
US8815798B2 (en) 2010-06-23 2014-08-26 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
BR112012033107A2 (pt) * 2010-06-23 2016-10-11 Novo Nordisk As derivados de insulina contendo ligações dissulfeto adicionais.
WO2012010553A1 (en) 2010-07-20 2012-01-26 Novo Nordisk A/S N-terminal modified fgf21 compounds
JP6058646B2 (ja) 2011-06-15 2017-01-11 ノヴォ ノルディスク アー／エス 多置換インスリン
EP2771026A4 (en) 2011-10-27 2015-08-05 Univ Case Western Reserve ULTRA-CONCENTRATED AND FAST-ACTING INSULIN ANALOG FORMULATIONS

Also Published As

Publication number Publication date
IL246757A0 (en) 2016-08-31
SA516371705B1 (ar) 2019-10-08
RU2684456C2 (ru) 2019-04-09
BR112016017193A2 (pt) 2017-10-03
WO2015128403A2 (en) 2015-09-03
DK3110840T3 (da) 2020-11-02
PL3110840T3 (pl) 2021-04-06
CN106459171A (zh) 2017-02-22
PT3110840T (pt) 2020-11-26
IL246757B (en) 2020-04-30
US10040839B2 (en) 2018-08-07
MX368387B (es) 2019-10-01
CA2941103A1 (en) 2015-09-03
RU2016135543A3 (es) 2018-08-30
AU2015222135A1 (en) 2016-07-28
HRP20201732T1 (hr) 2020-12-25
EP3110840A2 (en) 2017-01-04
KR20160125988A (ko) 2016-11-01
ES2831848T3 (es) 2021-06-09
RS61137B1 (sr) 2020-12-31
TW201620930A (zh) 2016-06-16
US20170008945A1 (en) 2017-01-12
RU2016135543A (ru) 2018-03-30
EP3110840B1 (en) 2020-10-21
HUE051355T2 (hu) 2021-03-01
JP2017508741A (ja) 2017-03-30
WO2015128403A3 (en) 2015-12-10
CN106459171B (zh) 2020-12-15
JP6580583B2 (ja) 2019-09-25
AR099569A1 (es) 2016-08-03
AU2015222135B2 (en) 2018-12-20
TWI686403B (zh) 2020-03-01
SI3110840T1 (sl) 2020-12-31

Similar Documents

Publication Publication Date Title
MX2016010899A (es) A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22.
ZA202406617B (en) Insulin containing pharmaceutical compositions
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
TN2017000011A1 (en) Aqueous formulation comprising paracetamol and ibuprofen.
PH12019502655A1 (en) Acylated insulin compound
ZA201805358B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX379201B (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12022551094A1 (en) Novel insulin analogues and uses thereof
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12021550834A1 (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
BR112017003425A2 (pt) composição farmacêutica para o tratamento de dor dentária ou mandibular aguda
MX2016002509A (es) Composicion farmaceutica de la combinacion de desloratadina con montelukast para ser administrada por via oral en forma farmaceutica tableta o en granulado, para el tratamiento de enfermedades respiratorias.
PL2852400T3 (pl) Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym, zastosowanie analogu insuliny, sposób dawkowania oraz sposób leczenia cukrzycy

Legal Events

Date Code Title Description
FG Grant or registration